肿瘤免疫中的NF-κB受体激活剂及其配体  

NF-κB receptor activators and their ligands in tumor immunity

作　　者：董玉欣 李茹雪 高峰 李敏 Dong Yuxin;Li Ruxue;Gao Feng;Li Min(College of Medical Imaging,Weifang Medical University,Weifang 261053,China;Graduate School of Jinzhou Medical University,Jinzhou 121012,China;Cheeloo College of Medicine,Shandong University,Biomedical Isotope Research Center,Ji′nan 250012,China;Department of Nuclear Medicine,960 Hospital of PLA,Ji′nan 250031,China)

机构地区：[1]潍坊医学院医学影像学院,潍坊261053 [2]锦州医科大学研究生院,锦州121012 [3]山东大学齐鲁医学院,生物医学同位素研究中心,济南250012 [4]联勤保障部队第九六0医院核医学科,济南250031

出　　处：《中华转移性肿瘤杂志》2023年第2期162-167,共6页Chinese Journal of Metastatic Cancer

基　　金：山东省自然科学基金面上项目(ZR2022MH017)

摘　　要：NF-κB受体激活剂配体(RANKL)/NF-κB受体激活剂(RANK)最早在免疫系统中发现,是一种多功能细胞因子,在肿瘤发生、进展尤其是骨转移中发挥重要作用。原发恶性肿瘤一旦发生骨转移则预后极差。地诺单抗是目前应用最为广泛的RANKL抑制剂,更多研究者试图以RANKL为靶点,寻求新型抗RANKL药物的同时实行RANKL特异性精准成像,推动原发肿瘤的早期诊疗进程。The receptor activators of NF-κB(RANK)and their ligands(RANKL)are a type of multifunctional cytokines,which were first discovered in immune system and found to play a vital role in tumorigenesis and progression,especially in bone metastasis.The prognosis is very poor once the primary tumor has bone metastases.Denosumab is the most widely used RANKL inhibitor,more researchers try to find a new anti-RANKL drug and implement specific precise imaging targeting RANKL,and pushing forward the early diagnosis and treatment of primary tumor.

关 键 词：NF-κB受体激活剂配体/NF-κB受体激活剂 肿瘤转移/骨 免疫机制 

分 类 号：R730.3[医药卫生—肿瘤]